Comparison of Ranibizumab versus Aflibercept in Treating Macular Edema among Patients with Serous Retinal Detachment Secondary to Branch Retinal Vein Occlusion

REFERENCES

• Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33:901–910.
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol. 2008;126:513–518.
   PubMed Web of Science ®Google Scholar
• Sekiryu T, Iida T, Sakai E, Maruko I, Ojima A, Sugano Y. Fundus autofluorescence and optical coherence tomography findings in branch retinal vein occlusion. J Ophthalmol. 2012;2012:e1–8.
   Google Scholar
• Noma H, Funatsu H, Mimura T, Shimada K. Visual function and serous retinal detachment in patients with branch retinal vein occlusion and macular edema: a case series. BMC Ophthalmol. 2011;11:29.
   PubMed Web of Science ®Google Scholar
• Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, Pearce I. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol. 2014;14:7.
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594–1602.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538–544.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1102–1112):e1101.
   Google Scholar
• Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278–284.
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–1032.
   PubMed Web of Science ®Google Scholar
• Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330–336.
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–809.
   PubMed Web of Science ®Google Scholar
• Georgalas L, Tservakis I, Kiskira E, Petrou P, Papaconstantinou D, Kanakis M. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: A 12-month prospective study. Cutan Ocul Toxicol. 2019;38:330–337.
   PubMed Web of Science ®Google Scholar
• Lee KH, Kang EC, Koh HJ. Dexamethasone intravitreal implant rescue treatment for bevacizumab refractory macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2017;31:108–114.
   PubMedGoogle Scholar
• Karacorlu M, Ozdemir H, Karacorlu SA. Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina. 2005;25:856–860.
   PubMed Web of Science ®Google Scholar
• Tsujikawa A, Sakamoto A, Ota M, et al. Serous retinal detachment associated with retinal vein occlusion. Am J Ophthalmol. 2010;149(291–301):e295.
   Google Scholar
• Yamaguchi Y, Otani T, Kishi S. Serous macular detachment in branch retinal vein occlusion. Retina. 2006;26:1029–1033.
   PubMed Web of Science ®Google Scholar
• Ota T, Tsujikawa A, Murakami T, et al. Subfoveal serous retinal detachment associated with extramacular branch retinal vein occlusion. Clin Ophthalmol. 2013;7:237.
   PubMedGoogle Scholar
• Cinal A, Ziemssen F, Bartz-Schmidt KU, Gelisken F. Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249:513–520.
   PubMed Web of Science ®Google Scholar
• Dogan E, Sever O, Çakır BK, Celik E. Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion. Clin Ophthalmol. 2018;12:1465.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol. 2009;148:e101.
   Web of Science ®Google Scholar
• Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six‐month results of a prospective randomized clinical trial. Acta Ophthalmol (Copenh). 2015;93:e29–e37.
   Web of Science ®Google Scholar
• Deissler HL, Lang GK, Lang GE. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res. 2014;122:20–31.
   PubMed Web of Science ®Google Scholar
• Battaglia MP, Isola V. Branch retinal vein occlusion and exudative retinal detachment: pathogenetical aspects. Ophthalmologica. 1994;208:29–31.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Lee JK, Klancnik JR JM, Gross NE. Optical coherence tomography of branch retinal vein occlusion. Retina. 2003;23:343–347.
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, Tatsugawa M, Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina. 2012;32:86–91.
   PubMed Web of Science ®Google Scholar
• Park SP, Ahn JK, Mun GH. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Retina. 2010;30:281–286.
   PubMed Web of Science ®Google Scholar
• Poon Y-C, Chen C-H, Kuo H-K, et al. Clinical implications of serous retinal detachment in branch retinal vein occlusion and response after primary intravitreal bevacizumab injection. J Ocul Pharmacol Ther. 2013;29:319–324.
   PubMed Web of Science ®Google Scholar
• Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, et al. Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol. 2013;251:9–14.
   PubMed Web of Science ®Google Scholar
• Kaldırım HE, Yazgan S. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Int Ophthalmol. 2018;38:1549–1558.
   PubMed Web of Science ®Google Scholar
• Pichi F, Elbarky AM, Elhamaky TR. Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol. 2019;39:145–153.
   PubMed Web of Science ®Google Scholar
• De Salles MC, Amrén U, Kvanta A, Epstein DL. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion: a randomized clinical trial. Retina. 2019;39:1370–1376.
   PubMed Web of Science ®Google Scholar